Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews

Alzheimer’s disease (AD) is the most common form of dementia over the age of 65. It is estimated that 115.4 million people will be affected by AD by 2050. Acetylcholinesterase inhibitors (AChEI) are the only available and approved treatment for AD. The aim of the present study was to analyse the evi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marta Pérez-Gómez Moreta, Natalia Burgos-Alonso, María Torrecilla, José Marco-Contelles, Cristina Bruzos-Cidón
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Acetylcholinesterase inhibitors Alzheimer’s disease cognition Overview of reviews Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/c82c630c2da340d2b249a41131bb54c6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c82c630c2da340d2b249a41131bb54c6
record_format	dspace
spelling	oai:doaj.org-article:c82c630c2da340d2b249a41131bb54c62021-11-25T16:50:50ZEfficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews10.3390/biomedicines91116892227-9059https://doaj.org/article/c82c630c2da340d2b249a41131bb54c62021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1689https://doaj.org/toc/2227-9059Alzheimer’s disease (AD) is the most common form of dementia over the age of 65. It is estimated that 115.4 million people will be affected by AD by 2050. Acetylcholinesterase inhibitors (AChEI) are the only available and approved treatment for AD. The aim of the present study was to analyse the evidence on the efficacy of the AChEI in the treatment of cognitive symptoms of Alzheimer’s disease. For that purpose, a review of review of the systematic reviews (SRs) on this topic was carried out by Web of Science, PubMed, and The Cochrane Library, among others, were searched until 24 September 2021. Thirteen of the 1773 articles evaluated the efficacy of AChEI on cognitive function and/or general condition and/or behavioural disturbances of patients with mild to moderate AD. Methodological quality and risk of bias were rated using the ROBIS scale. The quality of the identified studies was high for nine of them, unclear for two, and finally only in two of the 13 studies did we detect low quality. Overall, AChEI showed very low efficacy in improving cognition in patients with mild to moderate AD. Better results were obtained in improving global state, with donepezil being the most effective treatment. No improvements in behavioural disturbances were found. Few high-quality reviews provide clear evidence of the effects of AChEI on cognition, global change, behaviour, and mortality. The data suggest that AChEI stabilize or slow cognitive deterioration, improving global status. In addition, data indicate that the use of AChEI decreases mortality in patients with mild to moderate AD. However, there is no evidence that they improve patient behaviour. Donepezil is the best therapeutic alternative at a dose of 10 mg/day.Marta Pérez-Gómez MoretaNatalia Burgos-AlonsoMaría TorrecillaJosé Marco-ContellesCristina Bruzos-CidónMDPI AGarticleAcetylcholinesterase inhibitorsAlzheimer’s diseasecognitionOverview of reviewsBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1689, p 1689 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Acetylcholinesterase inhibitors Alzheimer’s disease cognition Overview of reviews Biology (General) QH301-705.5
spellingShingle	Acetylcholinesterase inhibitors Alzheimer’s disease cognition Overview of reviews Biology (General) QH301-705.5 Marta Pérez-Gómez Moreta Natalia Burgos-Alonso María Torrecilla José Marco-Contelles Cristina Bruzos-Cidón Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
description	Alzheimer’s disease (AD) is the most common form of dementia over the age of 65. It is estimated that 115.4 million people will be affected by AD by 2050. Acetylcholinesterase inhibitors (AChEI) are the only available and approved treatment for AD. The aim of the present study was to analyse the evidence on the efficacy of the AChEI in the treatment of cognitive symptoms of Alzheimer’s disease. For that purpose, a review of review of the systematic reviews (SRs) on this topic was carried out by Web of Science, PubMed, and The Cochrane Library, among others, were searched until 24 September 2021. Thirteen of the 1773 articles evaluated the efficacy of AChEI on cognitive function and/or general condition and/or behavioural disturbances of patients with mild to moderate AD. Methodological quality and risk of bias were rated using the ROBIS scale. The quality of the identified studies was high for nine of them, unclear for two, and finally only in two of the 13 studies did we detect low quality. Overall, AChEI showed very low efficacy in improving cognition in patients with mild to moderate AD. Better results were obtained in improving global state, with donepezil being the most effective treatment. No improvements in behavioural disturbances were found. Few high-quality reviews provide clear evidence of the effects of AChEI on cognition, global change, behaviour, and mortality. The data suggest that AChEI stabilize or slow cognitive deterioration, improving global status. In addition, data indicate that the use of AChEI decreases mortality in patients with mild to moderate AD. However, there is no evidence that they improve patient behaviour. Donepezil is the best therapeutic alternative at a dose of 10 mg/day.
format	article
author	Marta Pérez-Gómez Moreta Natalia Burgos-Alonso María Torrecilla José Marco-Contelles Cristina Bruzos-Cidón
author_facet	Marta Pérez-Gómez Moreta Natalia Burgos-Alonso María Torrecilla José Marco-Contelles Cristina Bruzos-Cidón
author_sort	Marta Pérez-Gómez Moreta
title	Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
title_short	Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
title_full	Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
title_fullStr	Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
title_full_unstemmed	Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews
title_sort	efficacy of acetylcholinesterase inhibitors on cognitive function in alzheimer’s disease. review of reviews
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c82c630c2da340d2b249a41131bb54c6
work_keys_str_mv	AT martaperezgomezmoreta efficacyofacetylcholinesteraseinhibitorsoncognitivefunctioninalzheimersdiseasereviewofreviews AT nataliaburgosalonso efficacyofacetylcholinesteraseinhibitorsoncognitivefunctioninalzheimersdiseasereviewofreviews AT mariatorrecilla efficacyofacetylcholinesteraseinhibitorsoncognitivefunctioninalzheimersdiseasereviewofreviews AT josemarcocontelles efficacyofacetylcholinesteraseinhibitorsoncognitivefunctioninalzheimersdiseasereviewofreviews AT cristinabruzoscidon efficacyofacetylcholinesteraseinhibitorsoncognitivefunctioninalzheimersdiseasereviewofreviews
_version_	1718412922949992448

Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews

Ejemplares similares